2809, 2020
Alpelisib and PIK3CA mutations: a new molecular targeted therapy for breast cancer is approved
On July 27, 2020, the European Medicines Agency authorised marketing [...]
2906, 2020
New European recommendations on DPD testing prior to anticancer therapy with fluoropyrimidines
Last April 30th, the European Medicines Agency (EMA) published recommendations [...]
1604, 2020
A new therapeutic opportunity treatment of NSCLC: the BRAF V600 mutation
FDA and EMA approved and reimbursed dabrafenib + trametinib combination [...]